Oncternal Therapeutics(ONCT) - 2023 Q2 - Earnings Call Transcript

There are no further questions at this time. And I would like to turn the floor back over to Dr. Breitmeyer for any closing comments. With that, thank you for joining us today, and we look forward to updating you during upcoming medical and banking conferences. Operator We are very excited to bring ONCT-534 to patients suffering from advanced prostate cancer soon. As a reminder, our preclinical study results suggest that ONCT-534 is active against the most common androgen receptor aberrations that drive tum ...